- Home
- Our Services
- Medical Device & IVD
- Drug Device Combination Products
Our Services
Drug-device combination products
Drug-device combination products are products that combine a drug and a medical device together — either as one single unit, co-packaged together, or labeled for use with each other. Common examples include insulin pens, drug-eluting stents, prefilled syringes, metered-dose inhalers, and nicotine patches. In the USA, the FDA’s Office of Combination Products (OCP) regulates them. In India, CDSCO oversees them. The key regulatory challenge is identifying the “primary mode of action” — whether the drug part or device part does most of the therapeutic work — because that determines which approval pathway you follow.
What Are Drug-Device Combination Products? (Simple Explanation)
Think of a drug-device combination product as a product that does two jobs at the same time — it uses a medical device to deliver a drug, or a drug to enhance how a device works. Neither part alone gives you the full treatment. You need both.
The US FDA defines a combination product as any therapeutic or diagnostic product that combines a drug, a medical device, and/or a biological product. These components can be physically joined together, sold together in the same box, or even sold separately but labeled to be used only together.
In India, the Central Drugs Standard Control Organisation (CDSCO) governs drug-device combination products under both the Drugs and Cosmetics Act and Medical Devices Rules 2017. Indian pharma and medtech companies often need to align their submissions with both FDA (for US exports) and CDSCO (for domestic approvals), making regulatory strategy critical.
The global demand for these products is growing fast — especially in areas like diabetes management, oncology, cardiology, and autoimmune disease treatment.
3 Main Types of Drug-Device Combination Products
Not all combination products are the same. Regulators classify them into three main types based on how the drug and device parts are connected:
Single-Entity (Integral) Products
Co-Packaged Products
Cross-Labeled Products
Understanding which type your product falls into is the first step in any regulatory strategy. It affects what kind of submission you file, what tests you need, and which regulatory center takes the lead role
Drug-Device Combination Products Examples: Full List
Here are the most common and well-known drug-device combination products you will find in hospitals, clinics, and homes across India and the USA today:
💉 Prefilled Syringes
Drug already loaded inside a syringe — ready to use. Widely used for vaccines, biologics, and insulin.
🖊️ Insulin Pens / GLP-1 Pens
Pen injectors for diabetes management. Ozempic, Lantus SoloStar, Humalog pens are popular examples.
❤️ Drug-Eluting Stents
Metal stents coated with a drug to stop arteries from re-narrowing after cardiac procedures.
🫁 Metered-Dose Inhalers (MDI)
The device (inhaler) delivers the drug directly to the lungs. Used for asthma and COPD.
💊 Transdermal Patches
Nicotine patches, fentanyl patches, or hormone patches — the device delivers the drug through skin.
🦴 Antibiotic Bone Cement
Bone cement loaded with antibiotics, used in joint replacement surgeries to prevent infection.
🧪 Drug-Eluting Catheters
Catheters coated with antimicrobial agents to reduce infection risk during medical procedures.
💉 Auto-Injectors (EpiPen)
Spring-loaded devices for self-injection in emergencies such as epinephrine for anaphylaxis.
📡 Smart On-Body Injectors
Wearable injectors like Neulasta Onpro that automatically deliver biologics and track doses via Bluetooth.
🧵 Drug-Coated Surgical Sutures
Sutures impregnated with antibiotics or anti-inflammatory drugs to reduce post-surgical complications.
🌬️ Nebulizers with Drug Solutions
When co-labeled with a specific drug for use only in that nebulizer, the combo becomes a combination product.
👁️ Drug-Eluting Ocular Inserts
Small devices placed in the eye to slowly release medication for conditions like glaucoma or dry eye.
How Are Drug-Device Combination Products Regulated? (FDA, EU MDR, CDSCO)
This is where most companies — especially first-time applicants — face the biggest confusion. The regulatory path depends on the product’s Primary Mode of Action (PMOA) — in simple words, which part of the product is doing the main therapeutic job.
Step 1: Determine Primary Mode of Action (PMOA)
Is the drug component doing most of the therapeutic work? Or is the device? This one question determines almost everything. If the drug is primary, the product follows drug regulations. If the device is primary, it follows medical device regulations.
| Regulatory Body | Country/Region | Lead Authority | Key Framework |
|---|---|---|---|
| FDA – OCP | 🇺🇸 USA | CDER, CDRH, or CBER (based on PMOA) | 21 CFR Part 3 & Part 4 |
| EMA / NCAs | 🇪🇺 European Union | Notified Bodies + EMA | EU MDR 2017/745 + Directive 2001/83/EC |
| CDSCO | 🇮🇳 India | CDSCO Drug/Device Division | Medical Devices Rules 2017 + Drugs & Cosmetics Act |
| PMDA | 🇯🇵 Japan | PMDA | Pharmaceutical and Medical Device Act |
How FDA Handles Combination Products
The FDA’s Office of Combination Products (OCP) is the central body that decides which of the three FDA centers takes the lead for review. The three centers are CDER (drugs), CDRH (devices), and CBER (biologics). The OCP also handles disputes and ensures consistent standards.
After the lead center is assigned, the sponsor must meet the current Good Manufacturing Practice (cGMP) requirements for both the drug part and the device part of the product. This dual compliance requirement is one of the biggest challenges manufacturers face.
EU MDR Approach: No Central Authority, But Clear Rules
Unlike the FDA, the EU does not have a single central authority for combination products. Under EU MDR 2017/745 and Directive 2001/83/EC, the regulation depends entirely on the primary mode of action. If the device part is primary, it falls under MDR and is assessed by a Notified Body. If the medicinal product is primary, the EMA and National Competent Authorities (NCAs) take over. The EMA’s CHMP handles the drug component review, and the MDCG handles the device component review.
India (CDSCO): Evolving Framework
For Indian manufacturers and companies exporting to India, CDSCO is strengthening its regulatory framework for combination products. The key challenge in India is that the line between drug regulation and device regulation sometimes overlaps. DPSRU (Delhi Pharmaceutical Sciences and Research University) is actively contributing to research in this area. If you are an Indian company aiming to export drug-device combination products to the USA, you will need to align your quality systems with both FDA 21 CFR requirements and Indian MDR 2017 standards simultaneously.
Biggest Regulatory Challenges in 2026
The combination products space is exciting — but it comes with real regulatory complexity. Here are the challenges that companies in India and the USA are dealing with right now:
- PMOA Classification Disputes: Determining whether a product is drug-led or device-led is often not obvious. Getting this wrong can mean filing the wrong application and losing months of time and significant budget.
- Dual Compliance (cGMP + QMS): You must meet both drug cGMP requirements (21 CFR 210/211) and device quality system requirements (ISO 13485 / 21 CFR Part 820) at the same time. This is complex to implement in a manufacturing facility.
- Leachables and Extractables Testing: When a drug sits inside a device (e.g., silicone in a prefilled syringe), the device materials can leach into the drug. This requires extensive testing to prove the drug remains safe and effective.
- Compatibility Studies: The drug and device components must be tested together — not just separately — to ensure they do not interact in harmful ways during manufacturing, storage, or patient use.
- Post-Market Safety Surveillance: Both the FDA (FAERS + MedWatch) and EMA (EudraVigilance) have specific adverse event reporting requirements for combination products. Non-compliance in post-market surveillance is a leading cause of enforcement actions.
- Smart Device Connectivity: New combination products with Bluetooth, app integration, and AI-powered dosing face additional cybersecurity and software-as-a-medical-device (SaMD) regulations that traditional combination products do not.
- Labeling Requirements: A combination product’s label must meet requirements from both drug and device labeling rules. Errors in labeling are a common cause of regulatory delays.
The Future of Drug-Device Combination Products (2026 and Beyond)
The future of drug-device combination products is being shaped by three powerful forces: smarter technology, more complex biologics, and greater demand for patient-centric self-administration.
1. Wearable & Connected Drug Delivery
On-body injectors with Bluetooth connectivity, smartphone apps, and real-time dose tracking are becoming mainstream. Products like the Neulasta Onpro kit, Skyrizi on-body injector, and next-generation smart insulin pens are redefining how patients manage chronic diseases at home — without visiting a clinic.
2. AI-Powered Dosing Systems
Artificial intelligence is being integrated into combination products to enable adaptive dosing. Automated Insulin Delivery (AID) systems combine a continuous glucose monitor (CGM), an insulin pump, and AI algorithms to automatically adjust insulin delivery — a true multi-component combination product. Regulatory agencies globally are developing new guidance for AI-driven medical products.
3. Biologics in High-Concentration Formats
Around 78% of FDA-approved monoclonal antibody combination products now use high-concentration formulations (above 100 mg/mL). Delivering these biologics without degradation requires advanced device engineering — especially in prefilled syringes and autoinjectors. This trend is creating new technical and regulatory demands.
4. Sustainability in Device Design
Single-use plastic devices are under scrutiny for environmental impact. Both the EU and US are pushing for reusable injection devices, take-back programs, and biodegradable materials. Future combination products will need to satisfy both safety and sustainability requirements — a balance that will require innovative design and new regulatory guidance.
5. Indian Manufacturing: A Growing Opportunity
India is positioned to become a major global manufacturer of combination products — especially prefilled syringes, auto-injectors, and drug-eluting devices. With the right regulatory strategy, Indian companies can access both domestic and international markets. TraccGlobal works directly with Indian manufacturers to build the compliance infrastructure needed to compete globally in this space.
How TraccGlobal Helps You Navigate Drug-Device Combination Products
Whether you are a pharma company in Mumbai, a medtech startup in Bengaluru, or a manufacturer in the USA looking to launch a combination product — TraccGlobal provides end-to-end regulatory support. We understand both the FDA’s combination product framework and India’s CDSCO requirements, so you get the right strategy from day one.
🔎 PMOA Determination
We help you clearly define whether your product is drug-led or device-led — the most critical step shaping your regulatory path.
📋 FDA Submission Support
From RFDs to 510(k), PMA, and NDA/BLA preparation — we manage the full FDA combination product submission process.
🇮🇳 CDSCO Registration
Support for CDSCO product registration, MDR 2017 classification, and compliance with global standards.
🏭 Dual cGMP Compliance
We build quality systems aligned with both 21 CFR drug cGMP and ISO 13485 device QMS.
🌍 EU MDR Strategy
Guidance on MDR 2017/745 pathway, Notified Body selection, and EMA consultation.
📊 Post-Market Surveillance
FAERS reporting, MDR monitoring, and post-market clinical follow-up support.
Frequently Asked Questions (FAQ)
What is the simplest definition of a drug-device combination product?
A drug-device combination product is any product that includes both a drug and a medical device, where both parts are needed to deliver the full treatment. The drug and device can be physically joined together, sold in the same package, or sold separately but labeled for use only together. Examples include insulin pens, prefilled syringes, drug-eluting stents, and asthma inhalers.
How does the FDA decide which center reviews a combination product?
The FDA’s Office of Combination Products (OCP) assigns the lead center based on the product’s primary mode of action (PMOA). If the drug component does most of the therapeutic work, CDER takes the lead. If the device is primary, CDRH leads. If a biologic is involved, CBER leads. Sponsors can request a formal designation from OCP if they are unsure. This decision is critical because it determines which regulations apply.
What are the most common drug-device combination products used in India?
In India, the most commonly used drug-device combination products include metered-dose inhalers (for asthma), insulin pens and prefilled syringes (for diabetes), transdermal patches (for pain management and hormone therapy), drug-eluting stents (for cardiac procedures), and auto-injectors. With India’s growing diabetes and cardiovascular patient base, the demand for these products is rapidly increasing.
Is a drug-eluting stent a drug or a device?
A drug-eluting stent is a combination product — it has both a device component (the metal or polymer stent) and a drug component (the drug coating that prevents re-narrowing of the artery). In the USA, the FDA classifies drug-eluting stents as device-led combination products, so CDRH typically takes the lead. The stent still requires evaluation of its drug component, but the primary regulatory framework is the medical device pathway (PMA).
Can Indian companies manufacture drug-device combination products for export to the USA?
Yes. Indian companies can and do manufacture combination products for the US market, but they must comply with FDA’s 21 CFR Part 4 cGMP requirements, which means implementing both drug cGMP (Parts 210/211) and device quality systems (ISO 13485). They may also need FDA facility registration, prior approval, and regular FDA inspections. TraccGlobal has experience helping Indian manufacturers build the systems and documentation needed for US market access.
What is the difference between PMOA and mode of action?
What is the future of drug-device combination products?
The future of drug device combination products is being shaped by connected wearable injectors with app integration, AI-driven dosing systems like automated insulin delivery, high-concentration biologic formulations, and sustainable reusable device platforms. GLP-1 therapies (like Ozempic and Wegovy) delivered via smart pens are one of the biggest growth drivers. Regulatory agencies globally are developing new guidance to keep up with this fast-moving space.
Our Services
Let Us Know Your Requirements
Call Emergency
+918868886774
What Our Clients Says
Real feedback from our happy clients about our quality and service.
